Skip to main content
Premium Trial:

Request an Annual Quote

Lynx Activates Genomics Deal With Hoechst AgrEvo


HAYWARD, Calif.--Lynx Therapeutics reached agreement on March 31 with Hoechst Marion Roussel and its affiliate Hoechst Schering AgrEvo to activate a subscription enabling AgrEvo to access a number of Lynx technologies. AgrEvo will pay a fee and minimum yearly subscription payments for Lynx's gene expression technologies, including Megaclone and its two derivatives, Megasort, and Massively Parallel Signature Sequencing (MPSS).

Megaclone allows simultaneous cloning of millions of DNA molecules or fragments in a sample and the parallel probing or assaying of resulting clones. Megasort is designed to extract from two related biological samples genes whose expressions differ between the samples. MPSS is designed to obtain 20 base signature sequences of nearly all genes expressed in a sample.

Lynx will receive $2 million from AgrEvo for non-exclusive access to the technologies, limited to the agricultural field. In addition, minimum subscription payments of $2 million per year will cover Lynx's costs plus profits for analyses to be performed by Lynx on behalf of AgrEvo. AgrEvo's subscription may be extended for up to three years beyond an initial one-year period.

Filed under

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.